Back to results
US 8,987,416 B2Granted
Viral fusion protein treatment for CCR8 mediated diseases
OwnerDavid A. Paslininventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerDavid A. Paslininventor
Estimating the term…
Compositions, methods, and kits are provided for treating CCR8 mediated diseases with applicability to atopic dermatitis and potential applicability to asthma, prurigo nodularis, nummular dermatitis, neurodermatitis, and lichen simplex chronicus and some lymphomas, multiple sclerosis, acquired immunodeficiency disease, peritoneal adhesions, Kaposi's sarcoma and atherogenesis—the expression of all of which, at least in part, is mediated by cells expressing the chemokine receptor CCR8. The compositions include proteins and fusion proteins from Molluscum contagiosum Virus (MCV) or variants, analogs and derivatives thereof which exhibit inhibitory activity. Examples of such MCV proteins are MC148 fusion protein (MC148fp) identified as MC148P-TAT-6×His (“6×His” disclosed as SEQ ID NO: 11), and its variants, fragments, analogs and derivatives which possess inhibitory activity. The variants, fragments, analogs and derivatives of MC148p and of MC148fp may be less than 100% homologous to MCV proteins as long as they are sufficiently homologous that inhibitory activity is preserved.
A method for treating a patient having at least one of atopic dermatitis and an atopic dermatitis-related disease, comprising:
A method for treating a patient having a CC chemokine receptor 8 (CCR8) mediated disease, comprising:
A method for treating a patient having at least one of atopic dermatitis and an atopic dermatitis-related disease comprising:
Dependencies are inferred from the claim text.